-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2025-06-17
Gensci Showcases BsADC Pipeline at 4th World ADC Asia SummitLearn More
-
2025-05-30
The FDA has Cleared the IND Application for GenSci128 for TP53 Y220C-Mutated Solid TumorsLearn More
-
2025-05-20
GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone LeaderLearn More
-
2025-03-21
Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.Learn More
-
2025-03-07
Episil® Launched in China: A Breakthrough Solution for Oral MucositisLearn More
-
2025-02-20
GenSci Submits Another Blockbuster Product for Market ApprovalLearn More